Search Results - "Kageji, Hideaki"

Synthesis and structure revision of litseaone A by Kageji, Hideaki, Mori, Naoki, Takikawa, Hirosato, Watanabe, Hidenori

“…Litseaone A, isolated from the stem barks of Litsea rubescens and Litsea pedunculata, is a chalcone derivative with a novel spiro-epoxide moiety. The…”
Get full text

Synthesis, activity, and their relationships of 2,4-diaminonicotinamide derivatives as EGFR inhibitors targeting C797S mutation by Kageji, Hideaki, Momose, Takayuki, Nagamoto, Yasuhito, Togashi, Noriko, Yasumatsu, Isao, Nishikawa, Yosuke, Kihara, Kawori, Hiramoto, Kumiko, Minami, Megumi, Kasanuki, Naomi, Isoyama, Takeshi, Naito, Hiroyuki

“…[Display omitted] The C797S mutation is one of the major factors behind resistance to the third-generation epidermal growth factor receptor (EGFR) tyrosine…”
Get full text

Concise synthesis of (±)-litseaones A and B by Kageji, Hideaki, Mori, Naoki, Takikawa, Hirosato, Watanabe, Hidenori

“…A concise synthesis of litseaones A and B, which were isolated from the stem barks of Litsea rubescens and L. pedunculata, is described in this study…”
Get full text

Discovery of a potent, selective, and orally available EGFR C797S mutant inhibitor (DS06652923) with in vivo antitumor activity by Kageji, Hideaki, Momose, Takayuki, Ebisawa, Masayuki, Nakazawa, Yusuke, Okada, Hiroyuki, Togashi, Noriko, Nagamoto, Yasuhito, Obuchi, Wataru, Yasumatsu, Isao, Kihara, Kawori, Hiramoto, Kumiko, Minami, Megumi, Kasanuki, Naomi, Isoyama, Takeshi, Naito, Hiroyuki, Tanaka, Naoki

“…[Display omitted] •The potency was successfully enhanced by the introduction of the basic substituents based on analysis of the docking study results.•The…”
Get full text

Abstract B173: Preclinical characterization and antitumor efficacy of DS-5010, a highly potent and selective RET inhibitor by Kaneta, Yasuyuki, Komatsu, Takahiro, Miyamoto, Masashi, Goto, Megumi, Namiki, Hidenori, Shibata, Yoshihiro, Kageji, Hideaki, Inagaki, Hiroaki, Nakayama, Kiyoshi, Tominaga, Yuichi, Isoyama, Takeshi

“…Background: RET gene rearrangement has been detected in several cancers including 1-2% and 50% of non-small cell lung cancer (NSCLC) and papillary thyroid…”
Get full text